1 / 17

Scleroderma Renal Crisis

Scleroderma Renal Crisis. Mathini Jayaballa Renal Advanced Trainee. Scleroderma Overview. Uncommon F>M, peak onset 3 rd - 5 th decade Uncontrolled accumulation of collagen and other CT proteins which leads to fibrosis in the skin and other visceral organs Widespread vascular lesions

fathia
Download Presentation

Scleroderma Renal Crisis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Scleroderma Renal Crisis Mathini Jayaballa Renal Advanced Trainee

  2. Scleroderma Overview • Uncommon • F>M, peak onset 3rd - 5th decade • Uncontrolled accumulation of collagen and other CT proteins which leads to fibrosis in the skin and other visceral organs • Widespread vascular lesions • Classification • Localised Scleroderma • Systemic Scleroderma – Limited and Diffuse

  3. Scleroderma Renal Crisis • Renal involvement 50%, usually mild: • proteinuria • mild elevation in Cr • HT • Severe renal disease 10-20% • diffuse cutaneousSSc >> LcSSc

  4. Clinical Features of Scleroderma Renal Crisis (SRC): • Occurs early – within 5 yrs • Can be the initial presentation SRC: • Progressive ARF • Abrupt onset mod-severe HTN • Urine sediment – usually bland

  5. Normal Renal Biopsy (H&E stain)

  6. SRC Renal Biopsy

  7. Normal SRC Renal Angiogram

  8. Risk Factors for SRC • Diffuse or advancing skin involvement • Glucocorticoid >15mg/day • Large joint contractures • New cardiac conditions • New onset anemia • Anti-RNA polymerase or fine speckled ANA pattern • Decreased prevalence of anti-centromereAb

  9. Characteristic Findings • New onset BP > 150/85 • Decline in renal function • New proteinuria +/- hematuria • Retinal changes of malignant hypertension • Flash pulmonary edema • MAHA +/- thrombocytopenia • CNS involvement - seizures

  10. Differentials: • TTP/HUS • ANCA-associated crescentic GN • D-penicillamine-related GN

  11. SRC Management • Untreated  ESKD 1-2mths, death in 1 yr • Prompt & aggressive BP control is mainstay of Rx • reduce BP <72hrs • ACE-I is 1st choice • Better renal function recovery & improves survival • Resistant / Malignant HTN – Add IV agent • Long term, low-dose ACE-I even if BP controlled • 10% normotensive Steen Ann Intern Med 1990; 113:352. Helfrich DJ, Arthritis Rheum 1989; 32:1128.

  12. SRC Progress • 20-50% progress to ESKD despite ACE-I • Inferior 5YS DSSc on dialysis: • 40% with SRC • 90% w/out SRC • Survival SSc on dialysis is worse than others • Delayed renal recovery possible • can take up to 18m Penn H, QJM 2007; 100:485. Abbott KC, J Nephrol 2002; 15:236.

  13. Transplantation Incident patients ANZ 2006-2010 (ANZDATA) • Better survival cf dialysis • 3YS 80% vs 55% • Worse survival than other primary diseases • Risk factors for recurrence/damage to allograft: • progressive skin thickening • new onset anemia • cardiac complications • Strategies to reduce recurrent disease • Avoid CNI, high dose steroids • Continue ACE-I indefinitely Gibney Am J Transplant 2004; 4:2027.

  14. PDGF PDGF Impaired angiogenesis / cell division PDGF Imatinib in Systemic Sclerosis • A protein tyrosine kinase inhibitor • Interferes with the signaling PDGF, TGF-β • Limited data on use in SSc or its effect on renal function

  15. Imatinib in Systemic Sclerosis • Case Report - Rx of refractory DcSSc • Improvement in skin thickening, physical function, FVC • Within 3m, maintained at 9m • Spiera et al - open-label prospective study • 30 patients with DcSSc, no controls • Improvement in skin thickening, FVC after 12m • Pope et al – double-blind RCT, proof-of-concept pilot study • Single center, active DcSSc • Only 10 pts enrolled • Early termination: poor tolerability, AE++ • No benefit in skin thickening, CRP/ESR, global assessment at 6m Sfikakis PP,Rheumatology (2008) 47 (5): 735-737. Spiera RF, Ann Rheum Dis 2011; 70:1003.

  16. Take home messages about SRC: • Rare but high M&M • Mainstay of Rx is BP control with ACE-I • High rate of progression to ESKD • Delayed renal recovery possible • Renal transplant should be considered

  17. References • Steen VD, Costantino JP, Shapiro AP, Medsger TA Jr. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990; 113:352. • Helfrich DJ, Banner B, Steen VD, Medsger TA Jr. Normotensive renal failure in systemic sclerosis. Arthritis Rheum 1989; 32:1128. • Penn H, Howie AJ, Kingdon EJ, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 2007; 100:485. • Abbott KC, Trespalacios FC, Welch PG, Agodoa LY. Scleroderma at end stage renal disease in the United States: patient characteristics and survival. J Nephrol 2002; 15:236. • Gibney EM, Parikh CR, Jani A, et al. Kidney transplantation for systemic sclerosis improves survival and may modulate disease activity. Am J Transplant 2004; 4:2027. • Spiera RF, Gordon JK, Mersten JN, et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 2011; 70:1003. • Kay J, High WA. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum 2008; 58:2543. • Sfikakis PP, Gorgoulis VG, Katsiari CG, et al. Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (2008) 47 (5): 735-737

More Related